Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04487080 · ClinicalTrials.gov registry record · Phase 3
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 3 study of Carcinoma, Non-Small Cell Lung, sponsored by Janssen Research & Development.
- Active
- Registry status
- Phase 3
- Development phase
- 1,074
- Enrollment target
- 20
- Study locations
NCT04487080 is a Phase 3 study of Carcinoma, Non-Small Cell Lung that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 1,074 participants, above the 316-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (240% higher). The trial reports 20 study locations across 16 states.
The verdict
NCT04487080, a Phase 3 study of Carcinoma, Non-Small Cell Lung, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,074 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the efficacy of the amivantamab and lazertinib combination, compared with osimertinib, in participants with epidermal growth factor receptor (EGFR) mutation (Exon 19 deletions \[Exon 19del\] or Exon 21 L858R substitution) positive, locally advanced or metastatic non-small cell lung cancer (NSCLC).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Osimertinib
- DRUG Amivantamab
- DRUG Lazertinib
Study Locations (20)
Arizona
- Arizona Oncology Associates, PC - HAL - Goodyear
- Yuma Regional Medical Center - Yuma
California
- City of Hope Long Beach Elm - Long Beach
- University of California Irvine - Orange
Minnesota
- Minnesota Oncology Hematology P A - Edina
- Mayo Clinic - Rochester
Texas
- Texas Oncology P A - Austin
- Oncology Consultants Texas - Houston
Colorado
- Rocky Mountain Cancer Centers - Lone Tree
Florida
- Cancer Specialists of North Florida - Jacksonville
Georgia
- University Cancer And Blood Center LLC - Athens
Louisiana
- East Jefferson General Hospital - Metairie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,074 participants |
| Start Date | 2020-09-30 |
| Est. Completion | 2027-06-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04487080
The ClinicalTrials.gov registry entry for NCT04487080 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,074 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 316-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (240% higher). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT04487080 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Arizona, California, Minnesota.
Frequently Asked Questions
What is clinical trial NCT04487080 about?
NCT04487080 is a clinical study titled "A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer". The purpose of this study is to assess the efficacy of the amivantamab and lazertinib combination, compared with osimertinib, in participants with epidermal growth factor receptor (EGFR) mutation (Exon 19 deletions \[Exon 19del\] or Exon 21 L858R substitution) positive, locally advanced or metastati...
What is the current status of trial NCT04487080?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,074 participants. The study started on 2020-09-30. Estimated completion is 2027-06-29.
What conditions does trial NCT04487080 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.
What interventions are being tested in trial NCT04487080?
The interventions under investigation include: Placebo (DRUG), Osimertinib (DRUG), Amivantamab (DRUG), Lazertinib (DRUG).
Who is sponsoring clinical trial NCT04487080?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04487080 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Non-Small Cell Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
-
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
RECRUITING · Phase 3
-
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.